A retrospective analysis of borderline ovarian tumors in a Greek University Hospital

Purpose: The aim of this retrospective study was to analyze the pathologic and clinical characteristics of borderline ovarian tumors. Methods/Results: During the period from January 1993 up to December 2002 we found 93 cases of borderline ovarian tumors. The mean age of patients was 44.3 years (range 28.9-59.7 years); 77.4%, 10.8% and 11.8% of patients had Stage 1, 11 and 111, respectively. The histological outcomes revealed 52.7% of serous and 41.9% of inucinous origin; 44.1% underwent radical Surgery, whereas 55.9% had unilateral salpingo-oophorectomy or cystectomy. The mean follow-up was 84 +/- 22 months. The overall five-year survival was 97.4% and 98% for mucinous and serous tumors, respectively. The survival rate was 100%, 90% and 81.8% in Stages I, II and III, respectively. Conclusion: From our results it can be concluded that borderline ovarian tumors have a favorable prognosis even after conservative management.

Borderline ovarian tumors; Management; Prognosis; Low malignant potential

[1] Cadron I., Amant F., VanGorp T., Neren P., Leunen K., Vergote I.: “The management of borderline tumours of the ovary”. Curr. Opin. Oncol., 2006, 18, 488.

[2] Seidman J.D., Soslow R.A., Vang R., Berman J.J., Stoler M.H., Sherman M.E. et al.: “Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images”. Hum. Pathol., 2004, 35, 918.

[3] Bell D.A., Longacre T.A., Prat J., Kohn E.C., Soslow R.A., Ellenson L.H. et al.: “Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives”. Hum. Pathol., 2004, 35, 934.

[4] Morice P.: “Borderline tumours of the ovary and fertility”. Eur. J. Cancer, 2006, 42, 149.

[5] Burks R.T., Sherman M.E., Kurman R.J.: “Micropapillary serous carcinoma of the ovary. A distinctive low grade carcinoma related to serous borderline tumors”. Am. J. Surg. Pathol., 1996, 20, 1319.

[6] Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C. et al.: “p53 and Ki-ras gene mutations in epithelial ovarian neoplasms”. Cancer Res., 1993, 53, 3103.

[7] Chan W.Y., Cheung K.K., Schorge J.O., Huang L.W., Welch W.R., Bell D.A. et al.: “Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers”. Am. J. Pathol., 2000, 156, 409.

[8] Shih I.-M., Kurman R.J.: “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis”. Am. J. Pathol., 2004, 164, 1511.

[9] Ayhan A., Guven S., Guven E.S., Kucukali T.: “Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?”. Acta Obstet. Gynecol. Scand., 2007, 86, 484.

[10] Engelen M.J., de Bruijn H.W., Hollema H., ten Hoor K.A., Willense P.H., Aalders P.G. et al.: “Serum CA125, carcinoembryonic antigen and CA 19-9 as tumor markers in borderline ovarian tumors”. Gynecol. Oncol., 2000, 78, 16.

[11] Kaern J., Trope C.G., Kristensen G.B., Abeler V.M., Pettersen E.O. et al.: “DNA ploidy; the most important prognostic factor in patients with borderline tumours of the ovary”. Int. J. Gynaecol. Cancer, 1993, 3, 349.

[12] Le-Ming S., Kurman R.J.: “Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges”. Clin. Cancer Res., 2005, 11, 7273.

[13] International Federation of Gynaecology and Obstetrics: “Annual report and results of treatment in gynaecologic cancer”. Int. J. Gynaecol. Obstet., 1989, 28, 189.

[14] Rota S.M., Zanetta G., Ieda N., Rossi R., Chiari S., Perego P. et al.: “Clinical relevance of retroperitoneal involvement from epithelial ovarian tumors of borderline malignancy”. Int. J. Gynecol. Cancer, 1999, 9, 477.

[15] Camatte S., Morice P., Thoury A., Fourchotte V., Pantier P., Lhomme C. et al.: “Impact of surgical staging in patients with macroscopic “Stage I” ovarian borderline tumors: analysis of a continuous series of 101 cases”. Eur. J. Cancer, 2004, 40, 1842.

[16] Seidman J.D., Kurman R.J.: “Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators”. Hum. Pathol., 2000, 31, 539.

[17] Yinon Y., Beiner M.E., Gotlieb W.H., Korach Y., Perri T., Ben- Baruch G.: “Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors”. Fertil. Steril., 2007, 88, 479.

[18] Odegaard E., Staff A.C., Langebrekke A., Engh V., Onsrud M.: “Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy”. Acta Obstet. Gynecol. Scand., 2007, 86, 620.

[19] Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., Mangioni C. et al.: “Behavior of borderline tumors with particular interest to persistence, recurrence and progression into invasive carcinoma: a prospective study”. J. Clin. Oncol., 2001, 19, 2658.